MUSHROOMS INC. 2025

2025 September Updates

Outstanding Shares: 39,435,760
(Unchanged since June of 2023)

Restricted: 26,445,148

Unrestricted: 12,990,612

Mushrooms Inc. September 2025 Update:
OTC: $MSRM

Dear Shareholders,

Mushrooms Inc. continues to strengthen its foundation—scientifically, structurally, and strategically. From disciplined share management to global R&D updates, we remain aligned in our mission to pioneer mycelium-powered wellness and therapeutics.

Shareholder Confidence: 1+ Year Without Dilution
Our share structure remains unchanged—**27 months and counting** with no new issuances since June 2023. Mushrooms Inc. has held steady at **39,435,760 outstanding shares**, reflecting our long-term commitment to shareholder value, market credibility, and responsible capital strategy.

In the world of OTC companies, where dilution is all too common, this track record reflects our **deep respect for shareholder value** and our **disciplined approach to growth**.

This commitment is especially noteworthy as we continue to build our startup venture with limited early-stage funding and revenue. Rather than dilute our shareholders, we've prioritized delivering real progress at each milestone—so that future infusions of capital come at increased valuations and benefit long-term investors.

We remain focused on creating value **without dilution**, until the science, partnerships, and traction demand the next level of strategic expansion.

MYCOLabX Update: The "Triple Threat" Bandage Nears Milestone

Our research partner in Germany is preparing a full October update on our **next-generation smart bandage**—a **patent-pending technology** designed to:

- **Prevent** infection using embedded antimicrobial properties.
- **Detect** infection in real time through **colorimetric change.**
- **Deliver** treatment directly to the wound site.

This integrated "**triple threat**" solution is engineered using mycelium as a carrier for nutrient delivery, pathogen monitoring, and targeted treatment. It reflects our broader scientific vision for **responsive, regenerative materials** across healthcare and advanced textiles.

We expect this update to align closely with final patent review stages and future grant applications in both U.S. and EU markets.

Grant & Funding Pathways: SPOKE / ARPA-H Engagement

Earlier this year, MYCOLabX applied to join the **SPOKE network** under the **ARPA-H** initiative—a national platform fostering rapid biomedical innovation. While we are **not yet a listed member**, our grant writing team remains in direct contact with SPOKE leadership and will continue efforts to integrate into this powerful funding and collaboration ecosystem.

What's SPOKE?
SPOKE (Secure Platforms for Open Knowledge Exchange) is a distributed network built to connect innovators, federal funders, and researchers working on critical health solutions. Membership facilitates:

- Access to a curated community of biomedical problem-solvers
- Participation in design sprints, pilot programs, and funding accelerators
- Support in navigating ARPA-H "customer experience" and milestone development

We’re optimistic about future participation, and in the meantime, our internal funding runway remains intact—with next-stage funding opportunities expected to open once we publish new technical data from Germany.

Looking Ahead: Smart Growth, Strong IP, Clean Capital Structure

The coming months will be critical as we:

- Receive updates from our European R&D team.
- Prepare for deeper product marketing and ecommerce.
- Advance FDA-adjacent documentation for the therapeutic bandage.
- Continue strategic communications with funding agencies and biotech partners.

We’re also awaiting feedback on our **initial patent filing**, with a decision expected in late Q4 2025 or early 2026.

Thank you for your belief in our vision. We move forward with **zero dilution**, **strong pipeline execution**, and a commitment to transforming wellness through the power of mushrooms.

Follow Us for Real-Time Updates To ensure you stay informed and engaged with $MSRM, follow our active social media channels:

- **X (Twitter)**: @MushroomsInc
- **Facebook**: https://www.facebook.com/shroomsinc
- **Instagram**: https://www.instagram.com/mushroomsforhealth
- **LinkedIn**: Kimberly Carlson, CEO

These platforms feature real-time shareholder news, public updates, R&D features, and CEO insights.

Thank you for your continued belief in our vision.

Warm regards,
Kimberly Carlson
CEO, Mushrooms Inc.
For more information, visit:

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition on adverse federal, state, and local government regulations, international governmental regulations, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.